Page last updated: 2024-09-05

o-(4-ethoxybutyl)berbamine and Leukemia

o-(4-ethoxybutyl)berbamine has been researched along with Leukemia in 1 studies

*Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gu, Y; Ma, T; Qiu, X; Xie, J; Xu, R; Yu, Y; Zhang, L; Zhang, X1

Other Studies

1 other study(ies) available for o-(4-ethoxybutyl)berbamine and Leukemia

ArticleYear
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Piperazines; Pyrimidines

2009